Oncology Institute beats Q4 revenue estimates, net loss narrows
Overview
U.S. oncology care provider's Q4 revenue grew 41.6% yr/yr, beating analyst expectations
Company's Q4 net loss narrowed compared to prior year
Adjusted EBITDA for Q4 turned positive, reflecting improved operations
Outlook
Company sees 2026 revenue between $630 mln and $650 mln
Company expects 2026 gross profit of $97 mln to $107 mln
Company anticipates 2026 adjusted EBITDA of $0 to $9 mln
Result Drivers
CAPITATED CARE EXPANSION - Co said growth was driven by continued expansion of its capitated care model and new payor partnerships
WORKING CAPITAL MANAGEMENT - Disciplined working capital management contributed to positive cash flow from operations in Q4
GROSS PROFIT MARGIN - Overall increase in gross profit margin supported improved operational results
Company press release: ID:nGNX5PdkFF
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $142 mln | $139.78 mln (4 Analysts) |
Q4 EPS |
| -$0.06 |
|
Q4 Net Income |
| -$7.5 mln |
|
Q4 Gross Profit |
| $22.7 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Oncology Institute Inc is $6.50, about 135.5% above its March 11 closing price of $2.76
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
